Pharmaceutical research: when active substance and target protein “embrace” each other

29-Jan-2021 - Scientists at Goethe University Frankfurt, together with colleagues from Darmstadt, Heidelberg, Oxford and Dundee (UK), have investigated how the fit of potent inhibitors to their binding sites can be optimised so that they engage longer with their target proteins. Long target residency has been ...

Drug suppresses spread of breast cancer

14-Dec-2017 - Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, report University of California San Diego School of Medicine and ...

Max Planck Society grants technology for cancer therapy

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center announce cancer research collaboration

18-Jul-2017 - Daiichi Sankyo, Max Planck Innovation, and the Lead Discovery Center have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center. This new ...

Origenis announces patent grants for lead small molecule LRRK2 inhibitors

Inhibitors scope on treatment of neurodegenerative and inflammatory diseases

29-May-2017 - Origenis GmbH announced that the US Patent Office has granted the company two important patents, US9,499,535 and US9,637,491, that protect the further development of small molecule inhibitor of LRRK2 (Leucine Rich Repeat Kinase 2) within the Company ́s CNS franchise. Michael Almstetter, CEO and ...

OCTIMET secures over EUR 11 million to develop its highly selective MET kinase inhibitors

19-Jan-2017 - OCTIMET Oncology NV, has secured EUR 11.3 million in a Series A investment round, enabling the company to accelerate the development of a clinically de-risked MET kinase inhibitor, as single agent or in combination with standard of care and targeted agents for the treatment of solid ...

Precision medicine breakthrough for Chronic Myeloid Leukaemia

15-Sep-2016 - Scientists at the University of Glasgow have made a second significant breakthrough in the treatment of chronic myeloid leukaemia – using precision medicine to kill more than 90% of chronic myeloid leukaemia (CML) stem cells. The results are published today in the high impact journal Cancer ...

Reader of epigenetic marks could be 'game changer' for certain cancers

20-Apr-2016 - If genes form the body's blueprint, then the layer of epigenetics decides which parts of the plan get built. Unfortunately, many cancers hijack epigenetics to modulate the expression of genes, thus promoting cancer growth and survival. A team of researchers led by Tatiana Kutateladze, PhD, ...

Identifying Another Piece in the Parkinson's Disease Pathology Puzzle

International Consortium Identifies and Validates Cellular Role of Priority Parkinson’s Disease Drug Target, LRRK2 Kinase

01-Feb-2016 - An international public-private research consortium has identified and validated a cellular role of a primary Parkinson’s disease drug target, the LRRK2 kinase. This important finding illuminates a novel route for therapeutic development and intervention testing for Parkinson’s, the second most ...

TAK-733 shows challenge of using a promising drug in the human body

15-Oct-2015 - A University of Colorado Cancer Center study reports "robust antitumor activity" of the drug TAK-733 in cells and mouse models of colorectal cancer. In all, 42 of 54 tested cell lines were sensitive to the drug, as were 15 of 20 tumors grown on mice from patient samples. Nine of these ...

New substance overcomes treatment-resistance in leukaemia

02-Dec-2014 - The chances of patients with Philadelphia chromosome-positive leukaemia (Ph+) being cured has greatly increased in recent years. Nevertheless, a high percentage of patients have developed resistance to available medication. But now, haematologists from Frankfurt, working with a Russian ...